Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Accumulated Expenses (2016 - 2024)

Cellectis has reported Accumulated Expenses over the past 6 years, most recently at $8.8 million for Q4 2024.

  • Quarterly results put Accumulated Expenses at $8.8 million for Q4 2024, down 5.74% from a year ago — trailing twelve months through Dec 2024 was $8.8 million (down 5.74% YoY), and the annual figure for FY2024 was $8.8 million, down 5.74%.
  • Accumulated Expenses for Q4 2024 was $8.8 million at Cellectis, down from $9.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CLLS hit a ceiling of $9.4 million in Q4 2022 and a floor of $8.8 million in Q4 2024.
  • Median Accumulated Expenses over the past 3 years was $9.4 million (2023), compared with a mean of $9.2 million.
  • Biggest five-year swings in Accumulated Expenses: decreased 0.56% in 2023 and later dropped 5.74% in 2024.
  • Cellectis' Accumulated Expenses stood at $9.4 million in 2022, then fell by 0.56% to $9.4 million in 2023, then fell by 5.74% to $8.8 million in 2024.
  • The last three reported values for Accumulated Expenses were $8.8 million (Q4 2024), $9.4 million (Q4 2023), and $9.4 million (Q4 2022) per Business Quant data.